Point of Care Coagulation Testing in Europe Shree Viswadia London, 9th December’ 2003 © 2003 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.

Agenda Introduction Agenda Overview of the Market Key Market Trends Market Size Key Market Forecasts Regional Trends Competitive Landscape Addressing the Challenges Take Home Comments Q & A

Overview of the Market Point of Care Testing 38.9% 5.2% 4.7% Self Testing 4.7% GP Based Testing Hospital POC Testing Lab Based Testing 61.1% 90.1% Note: All figures are rounded. Source: Frost & Sullivan

Key Market Trends POC in emergency and critical care Test Menus Connectivity Marketing & Distribution Agreements Laboratory Testing Sample Sizes Lack of Legislation POC Test Prices

Revenue (Euro million) Market Size 400 25 350 20 300 250 15 Revenue (Euro million) Growth Rate (%) 200 10 150 100 5 50 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Year

Key Market Forecasts Point of Care Testing: CAGR 18% Source: Frost & Sullivan Point of Care Testing: CAGR 18% Near Patient Testing: CAGR 17.6% Self Testing: CAGR 6% 2003 2009 Enoxaparin Card Launched Ximelagatran launched Reimbursement issues resolved Other DTI’s launched (GSK, Boehringer) DNA based testing

Market Potential 2003 650,000 Germany France UK Italy Spain Benelux Scandinavia Alps 270,000 170,000 172,000 64,000 750,000 520,000 600,000 Note: All figures are rounded. Source: Frost & Sullivan

Regional Trends Key Laboratory based Testing Near Patient Testing Self Testing Not included in Study Source: Frost & Sullivan

Competitive Landscape Whole Blood Analysers TEG ROTEM Other Self Testing Analysers Coaguchek S Protime INRatio Near Patient Testing Analysers Thrombotest Rapidpoint GEM I-Stat PCA Hemachron ACT III Automated Coaguchek Pro/ DM Sonoclot PFA 100 Source: Frost & Sullivan

Addressing the Challenges Challenges in Quality Control Home monitor results inconsistent with traditional laboratory results Attitudes of the Physicians as gatekeepers Reimbursement Schedules are inconsistent Development of Thrombin Inhibitor Drugs has potential of reducing customer base

Take-Home Comments Coagulation Testing steadily moving away from Traditional Testing POC coagulation testing market growing at CAGR 17.6% in Europe Opportunities

Thank you - Any Questions? Ask on the telephone - press * 1 on your keypad Ask online - use the Q&A tab on the left of your screen ( +44 (0)20 7343 8383 8 enquiries@frost.com : www.frost.com